Compare UK prices. 40+ products · 22 retailers scored
PeptideClear UK

NHS access decoder

NHS GLP-1 access by nation

OM

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-05-27

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

NHS access to GLP-1 weight-loss medications (semaglutide and tirzepatide, branded Wegovy and Mounjaro) differs by UK nation. England is rolling out tirzepatide in phased cohorts via primary care, with full eligibility scheduled to take 9 to 12 years. Scotland funds it only through specialist weight-management services at lower BMI thresholds. Wales is implementing slowly through specialist tiers. Northern Ireland has no funded NHS route at present. PeptideClear summarises each nation's current eligibility and access path, last reviewed May 2026.

POM: Prescription only medicine (POM). PeptideClear is a comparison and information service. We do not prescribe, dispense, or recommend medication for individuals. A qualified GMC-registered prescriber determines suitability after consultation.

England

Cohort 1 live since June 2025. Cohort 2 launches 23 June 2026.

BMI:
BMI 40+ for Cohort 1 (Cohort 2 expected to broaden to BMI 35+ with comorbidities).
Route:
GP referral to NHS weight management specialist service. No GP-prescribing route yet.
Medication:
Tirzepatide (Mounjaro) per NICE TA1026.

Phased rollout means most adults outside Cohort 1 cannot access NHS GLP-1 yet. Ethnicity-adjusted BMI applies (2.5 kg/m² lower for South Asian, Chinese, Black African, African-Caribbean populations).

Scotland

Cleared by SMC for use, BMI 30+ specialist-only.

BMI:
BMI 30+ in adults, with at least one weight-related comorbidity, in specialist services.
Route:
Specialist weight management service referral, not GP. Variation by health board.
Medication:
Tirzepatide (Mounjaro). Wegovy also approved.

Scotland uses Right Decisions guidance. Patients in Scotland may have lower BMI threshold than England, but capacity at specialist services is the bottleneck.

Wales

NICE TA1026 implementation in progress 2026.

BMI:
Following NICE TA1026 (BMI 35+ with comorbidity, ethnicity-adjusted).
Route:
Health board specialist service. Cardiff and Vale, Aneurin Bevan, Betsi Cadwaladr at different stages.
Medication:
Tirzepatide (Mounjaro).

Wales is implementing TA1026 on a slower timeline than England. Postcode-by-postcode variation by local health board.

Northern Ireland

No NHS GLP-1 access yet. First specialist service planned 2026.

BMI:
TBD. Likely to mirror NICE TA1026 once funding is in place.
Route:
Currently no NHS route. Patients must use private route.
Medication:
Pending.

Northern Ireland HSC has not yet announced an NHS GLP-1 weight management programme. Several private pharmacies dispense in NI but cold-chain delivery has postcode exclusions.

If NHS is not an option for you

Most UK adults wanting Mounjaro or Wegovy in 2026 cannot get it through the NHS yet. Three private routes exist, each with different costs and care levels. For how the cost is determined across these routes, see our GLP-1 cost and access guide.

Editorial

Baseline panels to track

If you are working with a UK private doctor or NHS prescriber on a peptide protocol, these are the blood panels typically ordered at baseline for GLP-1 medications. Not a recommendation for self-administered testing.

  • HbA1c. Baseline plus 12-week follow-up. The canonical metabolic marker tracked across UK NHS and private GLP-1 protocols. Captures glucose impact across a 90-day window.
  • Fasting glucose. Baseline establishes pre-treatment glucose handling. NHS specialist services and private clinics use this alongside HbA1c.
  • Lipid panel. Weight loss and GLP-1 therapy shift the lipid profile. Baseline allows the prescriber to track cardiovascular markers across the treatment cycle.
  • Weight and waist circumference. Not a blood panel, but the canonical adjunct measure. Waist circumference tracks visceral adiposity more sensitively than weight alone.

Affiliate links to UK lab providers. PeptideClear earns commission on bookings. Editorial selection independent. See how we are funded.

Popular on PeptideClear

Reviewed by Oliver Mackman, editorial director · last reviewed 2026-05-27T12:00:00.000Z
Trust, Legal and Governance

PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.

Legal and Registration

Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.

Standards and Governance

Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.

Domain Continuity

Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.